Forbius’s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis NEW YORK & MONTREAL– Bristol Myers Squibb (NYSE: BMY) and Forbius, a privately held, clinical-stage protein engineering company that designs and develops …
Trending at Lumira Ventures
Forbius Reported Safety and Initial Anti-Fibrotic Effects of First-in-Class, Selective TGF-beta Inhibitor, AVID200, in Phase 1b Systemic Sclerosis Trial at EULAR 2020
Initial results demonstrate anti-fibrotic effects of AVID200 as indicated by rapid and sustained declines in skin fibrosis. AVID200 was well-tolerated, and no dose-limiting toxicities, SAEs or adverse events greater than Grade 2 were observed. The MTD was not reached. AVID200 …
Forbius Completes Phase 1 Oncology Dose Escalation with AVID200
Austin, TX, and Montreal, QC (Nov. 8, 2019) – Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, today presented the first Phase 1 clinical data from its oncology development program with AVID200, in a late-breaking …
Forbius Completes Phase 1a Solid Tumor Trial Enrollment & Closes Series C Financing
Austin, TX, and Montreal, QC – Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, announced today that the Phase 1a solid tumor trial exploring the safety and tolerability of AVID200, a first-in-class TGF-beta 1 …
Health Canada Clears Forbius’ AVID100 to Commence Phase 2 Clinical Trials
Austin, TX and Montreal, QC (May 28, 2019) – Forbius, a clinical-stage company that develops novel biologics for the treatment of cancer and fibrosis, announced today that it has obtained approval from Health Canada to conduct Phase 2 clinical trials …
Forbius’ AVID200, a Novel TGF-beta 1 & 3 Inhibitor, Cleared by Health Canada to Commence Phase 1 Clinical Trial in Solid Tumors
Expansion of ongoing AVID200 Phase 1 solid tumor trial to include patients at clinical sites in Canada AVID200 is a rationally designed, highly potent inhibitor of TGF-beta 1 & 3, the principal oncogenic TGF-beta isoforms Best-in-class efficacy and safety potential …
Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor
Investigator-initiated trial to evaluate AVID200’s safety, anti-fibrotic activity, and ability to restore hematopoiesis in patients with myelofibrosis AVID200 is a rationally designed, highly potent inhibitor of TGF-beta 1 & 3, the principal drivers of fibrosis in myelofibrosis and other fibrotic …
Forbius Announces First Patient Dosed in Phase 2a Triple Negative Breast Cancer (TNBC) Trial of AVID100, a Novel, Tumor-Specific Anti-EGFR ADC
This trial evaluates the efficacy of AVID100 in TNBC patients with EGFR-overexpression 20% of TNBC patients highly overexpress EGFR; there is no approved targeted therapy AVID100 is the most advanced, broadly active anti-EGFR ADC in clinical development, targeting both wild-type …
Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing
AVID100 is the only clinical-stage anti-EGFR ADC that targets both wild-type and mutant forms of EGFR with limited off-tumor toxicity due to novel mechanism of action Phase 1 confirmed that AVID100 was well-tolerated and established a recommended phase 2 dose …
Forbius Announces First Patient Dosed in Phase 2a Squamous Cell Carcinoma of the Head and Neck (SCCHN) Trial of AVID100, a Novel Anti-EGFR ADC
This trial will evaluate the efficacy of AVID100 in SCCHN patients with EGFR IHC 3+ tumors AVID100 is the most advanced, broadly active anti-EGFR ADC in clinical development 20% of SCCHN patients highly overexpress EGFR; no therapy is approved for …
Forbius Announces the First Patient Dosed in a Phase 1b Diffuse Scleroderma Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor
This trial will evaluate the safety and anti-fibrotic effects of AVID200 in diffuse cutaneous systemic sclerosis patients AVID200 is a rationally designed, highly potent inhibitor of TGF-beta 1 & 3 TGF-beta 1 & 3 are the principal drivers of fibrosis …
Forbius Collaborates with the Icahn School of Medicine at Mount Sinai & the Myeloproliferative Neoplasm Research Consortium to Evaluate AVID200
MPN-RC sponsored, NIH-supported Phase 1/2 trial in myelofibrosis to commence imminently TGF-beta is a central driver of bone marrow fibrosis in myelofibrosis AVID200 selectively inhibits TGF-beta 1 & 3, the principal fibrotic TGF-beta isoforms, while sparing TGF-beta 2, a positive …
Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor
AVID200 is a rationally designed and highly potent TGF-beta 1 & 3 inhibitor Best-in-class efficacy and safety potential by selectively targeting principal oncogenic TGF-beta isoforms Reverses immunosuppression and renders tumors sensitive to checkpoint blockade in pre-clinical models Jan. 7, 2019 …
Forbius’ AVID200 IND Receives Clearance from the FDA to Start Phase 1 Scleroderma Clinical Trial
Forbius announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for AVID200, an isoform-selective TGF-β inhibitor. This enables the company to begin a Phase 1 clinical study to evaluate AVID200 as a potential treatment for diffuse cutaneous systemic …
Forbius (Formation Biologics) Awarded $18.8 Million Grant by the Cancer Prevention and Research Institute of Texas
Forbius (Formation Biologics) announced today that it has been awarded a Product Development grant totaling $18.75 million from the Cancer Prevention and Research Institute of Texas (CPRIT). The grant will support operations and Phase 2a development of AVID100, a highly …
- Page 1 of 2
- 1
- 2